Biotech traded modestly higher to start the week, with sentiment still selective rather than broad-based. Today’s BioBrief looks at obesity, MASH, oncology positioning ahead of ASCO, and continued market preference for commercial execution.

In today’s BioBrief:

• Eli Lilly / orforglipron — Lilly remained central to the obesity debate as investors continued focusing on whether oral GLP-1 therapies can become major products alongside injectable franchises like Zepbound and Mounjaro.
• Madrigal / Rezdiffra — Madrigal continued drawing attention as investors increasingly framed Rezdiffra not only as the first approved MASH therapy, but as a possible foundation for a broader liver disease franchise.
• Arrowhead / ARO-PNPLA3 — Madrigal’s licensed RNA interference program rema ...